Replimune Group, Inc. has disclosed a significant insider transaction involving the sale of 16,500 shares of common stock by Director Kapil Dhingra. This event, filed on November 2, 2026, is noteworthy as it provides insights into the company's internal dynamics and may influence investor sentiment.

Background

Replimune Group, Inc. is a company that specializes in the development of biological products, specifically in the area of immuno-oncology. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to Biological Products (No Diagnostic Substances). Replimune is publicly traded on the Nasdaq under the ticker symbol REPL.

What the Filing Says

According to the recent SEC filing, the sale of shares was executed on the same day as the filing. The total market value of the shares sold by Dhingra is reported to be approximately $292,875. The filing indicates that these shares were acquired through stock options, and the transaction was completed in cash.

Impact

This insider sale may have implications for various stakeholders, including investors and analysts who monitor insider trading activities as a barometer of company health. The transaction reflects ongoing activity among insiders, which can be interpreted in various ways by the market.

What's Next

The filing does not specify any subsequent actions or outcomes related to this transaction.